HUTCHMED Announces NMPA Approval for ORPATHYS

Summary by AI BETAClose X

HUTCHMED has received conditional approval from China's National Medical Products Administration for ORPATHYS® (savolitinib) to treat locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma patients with MET amplification who have failed at least two prior systemic treatments. This approval, supported by pivotal Phase II study data showing an objective response rate of 32.3%, marks the first selective MET inhibitor for this patient population in China. The drug demonstrated a disease control rate of 63.1%, a median time to response of 1.4 months, a median duration of response of 9.7 months, and a median progression-free survival of 4.0 months. This represents the third approved indication for ORPATHYS® in China, underscoring HUTCHMED's commitment to precision medicine and its proprietary R&D platform.

Disclaimer*

UK 100

Latest directors dealings